Khalkova Zh, Zaĭkov Kh, Khristeva V, Dinoeva S, Chipilska L
Probl Khig. 1992;17:122-30.
The acute toxicity of a new Bulgarian microbial preparation bulmoscid on the basis of Bacillus thuringiensis H-14 in the conditions of oral, dermal, inhalation and intraperitoneal introduction in experimental animals is determined. The assessment of toxicity is made by using toxicometric, integral, hematologic, histologic and microbiologic methods in accordance with Bulgarian and international criteria and standards. It is established, that the preparation bulmoscid introduced orally in dose 5500 mg.kg-1 (6.6.10(10) cell kg-1), applied dermally in dose 6000 mg/kg-1 (7.2.10(10) cells kg-1) and in concentrations 18 mg.m-3 (2.2.10(8) cells m-3) for 14 day inhalation exposure, provokes no lethal exit and symptoms of intoxication and leads to no changes in the integral, hematologic and histologic investigations on experimental animals. The preparation belongs to the practically nontoxic substances. The studies of the acute toxicity show, that the microbial preparation bulmoscid offers no danger for appearing of oral, dermal and inhalation poisonings when observing the regulations for its production and use.
测定了一种基于苏云金芽孢杆菌H-14的新型保加利亚微生物制剂bulmoscid在实验动物经口、经皮、吸入和腹腔注射情况下的急性毒性。根据保加利亚和国际标准，采用毒理学、综合、血液学、组织学和微生物学方法对毒性进行评估。结果表明，以5500 mg.kg-1（6.6×10(10) 个细胞/kg-1）的剂量经口给予制剂bulmoscid，以6000 mg/kg-1（7.2×10(10) 个细胞/kg-1）的剂量经皮应用，以及在浓度为18 mg.m-3（2.2×10(8) 个细胞/m-3）的情况下进行14天的吸入暴露，均未引发致死情况和中毒症状，且实验动物的综合、血液学和组织学检查未出现变化。该制剂属于实际无毒物质。急性毒性研究表明，当遵守其生产和使用规定时，微生物制剂bulmoscid不会造成经口、经皮和吸入中毒的危险。
